213-221
Mini Review
Hydroxyurea and hydroxamic acid derivatives as antitumor drugs
Nina Saban and Maro Bujak
223-232
Original Article
Zebularine suppresses the apoptotic potential of 5-fluorouracil via cAMP/PKA/CREB pathway against human oral squamous cell carcinoma cells
Maiko Suzuki, Fumiaki Shinohara, Manabu Endo, Masaki Sugazaki and Seishi Echigo, et al.
233-241
Original Article
Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients
Pol M. Specenier, Tudor Ciuleanu, Jane E. Latz, Luna C. Musib and Christelle L. S. Darstein, et al.
243-251
Original Article
Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study
Patrick A. Thompson, Gary L. Rosner, Katherine K. Matthay, Theodore B. Moore and Lisa R. Bomgaars, et al.
253-261
Original Article
Enhancement of the in vivo antitumor activity of clofarabine by 1-β-d-[4-thio-arabinofuranosyl]-cytosine
William B. Parker, Sue C. Shaddix, Karen S. Gilbert, Rodney V. Shepherd and William R. Waud
263-270
Original Article
Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus
Joseph Boni, Richat Abbas, Cathie Leister, Jaime Burns and Ronald Jordan, et al.
271-277
Original Article
Changes of host immunity in relation to efficacy in liver cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy
Kouichi Momiyama, Hidenari Nagai and Yasukiyo Sumino
279-285
Original Article
Protein nitration, PARP activation and NAD+ depletion may play a critical role in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis in the rat
Premila Abraham and Suganthy Rabi
287-295
Original Article
Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies
Monica Mita, Alain Mita, John Sarantopoulos, Chris H. Takimoto and Eric K. Rowinsky, et al.
297-300
Original Article
Biweekly docetaxel in recurrent ovarian cancer: a phase I dose finding study
Johanna Mäenpää and Arto Leminen
301-306
Original Article
Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer
Katia Lorizzo, Nicola Fazio, Davide Radice, Sabrina Boselli and Leonardo Ariu, et al.
307-316
Original Article
Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro
Kate Connolly, Richard Mitter, Morwenna Muir, Duncan Jodrell and Sylvie Guichard
317-325
Original Article
Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study
Kyung Hee Lee, Min Kyoung Kim, Yeol Hong Kim, Baek Yeol Ryoo and Ho Yeong Lim, et al.
327-333
Original Article
Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma
Youling Gong, Li Ren, Lin Zhou, Jiang Zhu and Meijuan Huang, et al.
335-340
Original Article
Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates
Lindsay B. Kilburn, Peter L. Bonate, Susan M. Blaney, Leticia McGuffey and Jed G. Nuchtern, et al.
341-346
Original Article
Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer
Satoru Tanaka, Takehiro Nohara, Mitsuhiko Iwamoto, Kazuhiro Sumiyoshi and Kousei Kimura, et al.
347-353
Original Article
A phase I/II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer
Kyoung Ha Kim, Young Suk Park, Myung Hee Chang, Hyo Song Kim and Hyun Jung Jun, et al.
355-360
Original Article
TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin
Jong Gwang Kim, Sang Kyun Sohn, Yee Soo Chae, Hong Suk Song and Ki-Young Kwon, et al.
361-369
Original Article
Open AccessPhase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes
Takanori Ishida, Takayoshi Kiba, Motohiro Takeda, Kotone Matsuyama and Satoshi Teramukai, et al.
371-377
Original Article
A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer
Hyun Jung Kim, Nam Su Lee, Sang-Cheol Lee, Sang Byung Bae and Chan Kyu Kim, et al.
379-384
Original Article
A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma
Joaquín Casal Rubio, S. Vázquez, F. Vázquez, M. Amenedo and J. L. Fírvida, et al.
385-390
Original Article
Fixed-dose rate infusion of gemcitabine and weekly cisplatin in elderly or poor performance status patients with unresectable non-small cell lung cancer
Gyeong-Won Lee, Myung-Hee Kang, Hoon-Gu Kim, Jung Hun Kang and Seok Hyun Kim, et al.
391-398
Original Article
Open AccessTopoisomerase I and IIα protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy
Nicolas Tsavaris, Andreas Lazaris, Christos Kosmas, Panagiotis Gouveris and Nikolaos Kavantzas, et al.
399
Erratum
Topoisomerase I and IIα protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy
Nicolas Tsavaris, Andreas Lazaris, Christos Kosmas, Panagiotis Gouveris and Nikolaos Kavantzas, et al.
401-406
Original Article
Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial
Peter Schmid, J. Krocker, R. Kreienberg, P. Klare and K. Kittel, et al.
407-412
Clinical Trial Report
Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer
S. H. Waters, A. Gillibrand, H. Berry, S. Kumar and G. Velikova, et al.
413-418
Short Communication
In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B
Khalid Abu Ajaj, Ralph Graeser, Iduna Fichtner and Felix Kratz
419-424
Short Communication
The glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells
Alessandro Ascione, Maurizio Cianfriglia, Maria Luisa Dupuis, Alessandra Mallano and Andrea Sau, et al.
425-429
Short Communication
A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours
Edwina N. Scott, Anne L. Thomas, L. Rhoda Molife, Samreen Ahmed and Sarah Blagden, et al.
431-432
Letter to the Editor
Anthocyanins-based drugs for colon cancer treatment: the nutritionist’s point of view
Fabio Galvano, Federico Salamone, Anna Nicolosi and Paola Vitaglione